MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Down Round

    Financing at a lower per-share price than the previous round.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    A down round prices new shares below the prior round's price per share, typically triggering anti-dilution adjustments and signaling that the company has missed expectations.
    What the regulation says
    While "down rounds" are a financial concept, their underlying causes, such as failed pivotal trials or significant post-market safety signals, directly relate to regulatory compliance and quality system effectiveness. Regulatory bodies like the FDA expect companies to maintain robust design controls as per 21 CFR 820.30 and conduct thorough clinical investigations, as outlined in 21 CFR Part 812, to minimize such failures. Poor cybersecurity leading to product recalls could also trigger a down round, highlighting the importance of cybersecurity risk management per FDA guidance.

    What this means in practice

    MedTech down rounds frequently follow failed pivotal trials, FDA non-clearances, or post-market safety signals. A well-structured 'pay-to-play' can keep insiders engaged and prevent worst-case dilution math.

    Examples

    • A MedTech startup fails to secure FDA 510(k) clearance for its new diagnostic device after unexpected clinical trial results, leading to a down round for its next funding round.
    • A company faces a significant product recall due to a manufacturing defect traced back to poor quality controls, resulting in a devaluation and a subsequent down round.
    • A post-market surveillance report reveals a previously unknown safety issue with an implanted device, requiring extensive remediation efforts and causing investors to re-price the company in a down round.
    Common pitfalls
    • •Failing to understand that a down round often signals underlying issues in regulatory strategy, quality management, or product development lifecycle.
    • •Assuming that financial remedies like "pay-to-play" provisions negate the need for addressing the root causes related to regulatory non-compliance or product quality.
    • •Neglecting to perform a thorough post-market surveillance and corrective and preventive action (CAPA) process after a significant product issue, which could lead to a down round.
    • •Underestimating the impact of regulatory non-compliance fines or market withdrawals, which can be precursors to a down round, on investor confidence.
    • •Not recognizing that repeated down rounds can indicate systemic problems in a company's ability to meet regulatory milestones or product performance expectations.

    Frequently asked questions

    Regulatory failures, such as a product not receiving FDA clearance or approval following a pivotal trial, can significantly diminish a company's valuation, leading to a down round. These failures indicate that the product may not meet safety and efficacy requirements, impacting its market viability.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    Cooley GO·1NVCA·1SVB·1
    1. 1
      Cooley GO: down rounds
      Verified
      Cooley GOcooleygo.com
    2. 2
      NVCA Model Documents
      Verified
      NVCAnvca.org
    3. 3
      Silicon Valley Bank - Healthcare Reports
      Verified
      SVBsvb.com

    Inline markers like [1] jump to the matching reference above.